ClinicalTrials.gg
Not yet recruitingNCT07048886Updated Jul 3, 2025

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

A Phase 4 interventional study of Rocklatan (netarsudil 0.02% and latanoprost 0.005%) and Systane in Primary Open Angle Glaucoma, sponsored by Center for Sight Las Vegas. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Center for Sight Las Vegas · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Planned enrollment
11th of 17
68 · median 85
Started
2025
with 3 others
Phase 4
5 of 17
3 open now
Registered
14th of 17
by date
Lead sponsor
1 of 17
Center for Sight Las Vegas

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 11th largest by planned enrollment, is one of 4 that started in 2025, is one of 5 in phase 4, and was the 14th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.

Read the detailed description

The study is a prospective single-practice with multiple locations, single-surgeon, parallel double arm study in subjects with open angle glaucoma (OAG), who were implanted with Hydrus microstent combined with cataract surgery to be randomized to receive Rocklatan vs. Comparator (artificial tears). Unmedicated MDIOP (mean diurnal intraocular pressure) measurements will be assessed at baseline (after Hydrus, prior to study medication) and at 1-month post-initiation of Study Drop.

03

Conditions studied

  • Primary Open Angle Glaucoma

Browse trials for

Keywords

  • Primary Open Angle Glaucoma
  • Rocklatan
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40 years and older
  • Subjects who have mild to moderate Open Angle Glaucoma (OAG)
  • Subjects who have undergone uncomplicated cataract surgery and Hydrus microstent implantation > 3 months prior to screening and within the last 2 years
  • Post-Hydrus subjects on 0-2 ocular hypotensive medication classes who can safely washout (if on ocular hypotensive medications)
  • Unmedicated or washed out IOP range between 16-26 mmHg

Exclusion criteria

Exclusion Criteria:

  • History of intraocular surgery except for uneventful refractive surgery or uncomplicated cataract surgery and hydrus microstent implantation
  • Prior Selective Laser Trabeculoplasty (SLT) within 18 months of surgery
  • Secondary glaucoma excluding pseudoexfoliation and pigmentary dispersion syndrome
  • Severe Open Angle Glaucoma
  • Narrow angles, other angle abnormalities or angle closure glaucoma
  • Allergy or intolerance to Rocklatan
  • History of corneal edema, or corneal disease or dystrophy
  • Current or history of intra-ocular infection or inflammation
  • History of retinal diseases that could affect diagnostic testing
  • Anticipated use of intra-ocular or topical not associated with the study protocol
  • Pregnant, breastfeeding or planning to become pregnant during the study
  • Any condition in the opinion in the investigator that would potentially confound the results of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Comparator Systane Artificial Tears

    Comparator arm is Systane artificial tears

    Drug: Systane

  • Active comparator
    FDA Approved Rocklatan (netarsudil 0.02% and latanoprost 0.005%)

    FDA approved Rocklatan (netarsudil 0.02% and latanoprost 0.005%) is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

    Drug: Rocklatan (netarsudil 0.02% and latanoprost 0.005%)

Interventions

  • DrugRocklatan (netarsudil 0.02% and latanoprost 0.005%)

    Drug page: NetarsudilStudies of NetarsudilNetarsudil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Additional intraocular eye pressure lowering post-Hydrus

  • DrugSystane

    Placebo Comparator (artificial tears)

06

What researchers measure

Primary outcomes

  1. Mean diurnal intraocular pressure change from baseline

    After Hydrus prior to study initiation drop

    Time frame: After 28 days up to 35 days post initiation of Rocklatan vs placebo comparator

Secondary outcomes

  1. Diurnal Intraocular pressure change from baseline and difference between intraocular pressure at each time point

    Goldmann Applanation Tonometry

    Time frame: After Hydrus prior to study drop and after 28 days up to 35 days post initiation of study drop for all time points 8am, 10am, 4pm (± 1 hour) between groups

Other outcomes

  1. Change in corneal hysteresis from baseline

    Ocular Response Analyzer

    Time frame: Change from baseline after 28 days up to 35 days post initiation of study drop

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — We do not plan to share individual participant data due to concerns about participant privacy and confidentiality.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Dec 2026, 17 months later.

Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2025
First posted
Jul 3, 2025
StartEst.
Jul 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07048886
Lead sponsor
Center for Sight Las Vegas
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Jul 15, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 3, 2025

Study contacts

Clinical Research Manager
Contact
jodi.kennedy@c4slv.com
702-724-2005
Clinical Research Coordinator
Contact
702-724-2067
Medical Director, Medical Doctor
principal investigator · Center For Sight

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion